Abstracts Archive - Page 975 of 2425 - ACR Meeting Abstracts

Abstract Number: 310 • 2019 ACR/ARP Annual Meeting
Efficacy, Immunogenicity and Cost Analysis of a Systematic Switch from Originator Infliximab to Biossimilar CT-P13 of All Patients with Inflamatory Arthritis from a Single Center
Ana Valido¹, Joana Silva-Dinis ², Maria João Saavedra ¹, Inês Iria ³, João Gonçalves ³, João Cruz ⁴, Nuno Bernardo ⁵ and João Eurico Fonseca ², ¹Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, CHLN; Lisboa, Portugal., Lisbon, Portugal, ²Rheumatology and Bone Diseases Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte; Unidade de Investigação em Reumatologia, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa; Centro Académico de Medicina de Lisboa; Lisbon, Portugal., Lisbon, Portugal, ³Faculdade de Farmácia da Universidade de Lisboa; Portugal, Lisbon, Portugal, ⁴Associate Professor with Habilitation, Faculdade de Farmácia da Universidade de Lisboa, Portugal, Lisbon, Portugal, ⁵Unidade de Negociação – Serviço de Gestão de Compras, Hospital Santa Maria, CHLN, Lisboa, Portugal., Lisbon, Portugal
Background/Purpose: Biotechnological drugs are a fundamental resource for the treatment (Tx) of rheumatic patients (Pts). Biosimilar drugs are intended to be as effective as the…
Abstract Number: 311 • 2019 ACR/ARP Annual Meeting
Documenting Bone Health for Veterans with Rheumatoid Arthritis in an Outpatient Academic Clinic: A Multiphase Quality Improvement Project
Melissa DeFoe¹, Rabih Nayfe ², Una Makris ³, Rashmi Arora ³ and Swathi Reddy ³, ¹VA North Texas Health Care System, Dallas, TX, ²University of Texas Southwestern Medical Center, Dallas, TX, ³University of Texas Southwestern Medical Center and the VA North Texas Health Care System, Dallas, TX
Background/Purpose: Rheumatoid Arthritis (RA) is associated with an increased risk of osteopenia and osteoporosis, which may result in fragility fractures and significant cost and morbidity. …
Abstract Number: 312 • 2019 ACR/ARP Annual Meeting
Timely Glucocorticoid Tapering in Vasculitis: A Need for Improved Knowledge Translation to Limit Toxicity
Arielle Mendel¹, Daniel Ennis ², Shirley Lake ³, Simon Carette ⁴ and Christian Pagnoux ⁴, ¹Mount Sinai Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, Sunnybrook Hospital, Toronto, ON, Canada, ⁴Mount Sinai Hospital and University Health Network, Toronto, ON, Canada
Background/Purpose: High dose glucocorticoids (GC) are part of the initial treatment of ANCA-associated (AAV) and large vessel vasculitides (LVV). Prompt subsequent tapering limits toxicity. Adherence…
Abstract Number: 313 • 2019 ACR/ARP Annual Meeting
Screening and Treating Hyperlipidemia in Patient’s on Tofacitinib, Tocilizumab, Sarilumab, and Baricitinib
William Torelli¹, James Ross ², Thomas Quinn ², Kourtney Erickson ¹, Andrea Soliman ¹ and Attiya Harit ³, ¹Lehigh Valley Health Network, Allentown, PA, ²lehigh valley health network, allentown, ³lehigh valley health organization, allentown
Background/Purpose: Background/Purpose: Tofacitinib and baricitinib (JAK inhibitors) are agents used for rheumatoid arthritis (RA), seronegative spondyloarthropathy (SpA), and juvenile idiopathic arthritis (JIA). Tocilizumab and sarilumab…
Abstract Number: 314 • 2019 ACR/ARP Annual Meeting
Pre-treatment Screening for Hepatitis B and C Among Users of Biologics or New Synthetic Disease Modifying Drugs: An Analysis Using RISE Data
Jing Li ¹, Julia Kay ¹, Jinoos Yazdany ¹ and Gabriela Schmajuk², ¹UCSF Division of Rheumatology, San Francisco, CA, ²UCSF, SFVAMC Division of Rheumatology, San Francisco, CA
Background/Purpose: Testing for hepatitis B virus (HBV) and hepatitis C virus (HCV) is recommended for patients initiating biologics or new synthetic DMARDs, which can increase the risk…
Abstract Number: 315 • 2019 ACR/ARP Annual Meeting
Improving the Rate of Tuberculosis Screening Among High Risk Rheumatoid Arthritis Patients on Biologic Agents Using a Proposed Questionnaire
Hamayon Babary¹, Suraiya Afroz ¹, John Carter ¹, Yih Lin ¹, Marie O'Brien ², Marcos Maldonado ¹, Helen Bateman ¹, Gabriela Montes-Rivera ¹, Grace Berlin ², Dan Tseytlin ², Madeline MacDonald ³, Yasmin Ayoubi ⁴, Matthew Nguyen ⁴, Shalini Setty ⁴, Rahul Mhaskar ⁴ and Joanne Valeriano-Marcet ¹, ¹University of South Florida Division of Rheumatology, Tampa, FL, ²Lehigh Valley Health Network, Allentown, PA, ³University of South Florida, College of Medicine, Tampa, FL, ⁴University of South Florida College of Medicine, Tampa, FL
Background/Purpose: The use of biologics has transformed the treatment paradigm for RA; however, reactivation of Mycobacterium Tuberculosis is still a concern. Frequent TB screenings without…
Abstract Number: 316 • 2019 ACR/ARP Annual Meeting
Implementation of Cardiovascular Screening in Hispanic Patient Population with RA, SLE and PsA
Liliya Gandrabur¹, Woo Young Kim ¹, Aditi Sen ¹, Deana Nes ¹, Julia Ash ¹, Amy Wasserman ¹ and Kirk Sperber ¹, ¹Westchester Medical Center, Valhalla, NY
Background/Purpose: Evidence suggests that the tools used for cardiovascular disease (CVD) risk assessment in the general population underestimate the true risk when they are applied…
Abstract Number: 317 • 2019 ACR/ARP Annual Meeting
Improving Adherence to Pregnancy Screening in Patients on Teratogenic Medications Using an Electronic Medical Record Alert System: A Quality Improvement Initiative
Vy Do¹, MaiLan Nguyen ¹, Keiji Akamine ², Julie Fuller ¹, Lorien Nassi ¹, Tracey Wright ³ and Katie Stewart ¹, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²Tokyo Metropolitan Children's Medical Center, Tokyo, Japan, ³University of Texas Southwestern, Texas Scottish Rite Hospital for Children, Children's Health, Dallas, TX
Background/Purpose: Mycophenolate is widely prescribed in the rheumatology setting. However, usage of mycophenolate during the first trimester of pregnancy is associated with an increased risk…
Abstract Number: 318 • 2019 ACR/ARP Annual Meeting
Improving Safe Prescribing of Hydroxychloroquine in a Safety Net Hospital Rheumatology Clinic
Francine Castillo¹, Michael Dodge ¹, Jung Hee Noh ², Laura Trupin ¹, Jinoos Yazdany ³ and Sarah Goglin ³, ¹University of California, San Francisco, San Francisco, CA, ²Zuckerberg San Francisco General Hospital, San Francisco, CA, ³UCSF Division of Rheumatology, San Francisco, CA
Background/Purpose: Hydroxychloroquine (HCQ) prescribing is standard of care for patients with SLE. The main potential side effect is retinal toxicity, especially at higher doses and…
Abstract Number: 319 • 2019 ACR/ARP Annual Meeting
A Pragmatic Randomized Trial to Improve Safe Dosing of Hydroxychloroquine
Milena Gianfrancesco¹, Sara Murray ¹, Michael Evans ², Gabriela Schmajuk ³ and Jinoos Yazdany ⁴, ¹University of California, San Francisco, San Francisco, ²University of California San Francisco, San Francisco, ³UCSF, SFVAMC Division of Rheumatology, San Francisco, CA, ⁴UCSF Division of Rheumatology, San Francisco, CA
Background/Purpose: Although generally well tolerated, the long-term use of hydroxychloroquine (HCQ) may lead to irreversible and potentially vision-threatening retinal toxicity. The American Academy of Ophthalmology…
Abstract Number: 320 • 2019 ACR/ARP Annual Meeting
Hydroxychloroquine (HCQ) Prescribing Habits and Provider Opinion on Dosing Guidelines in the Rheumatology and Dermatology Practices of an Academic Institution
Rebecca Overbury¹, Jakrapun Pupaibool ², Christopher Hansen ³, Daniel Clegg ⁴ and Dorota Lebiedz-Odrobina ⁵, ¹Assisstant Professor, University of Utah, Salt Lake City, UT, ²University of Utah, Division of Infectious Diseases, Salt Lake City, UT, ³University of Utah, Department of Dermatology, Salt Lake City, UT, ⁴University of Utah, Salt Lake City, UT, ⁵University of Utah, Division of Rheumatology, Salt Lake City, UT
Background/Purpose: Research has shown potential retinal toxicity rates from HCQ as high as 7.5%. Research suggests toxicity is dose-related. In 2016, the American Academy of…
Abstract Number: 321 • 2019 ACR/ARP Annual Meeting
Adherence to Weight-Based Dosing Guidelines in Patients Receiving Hydroxychloroquine for Rheumatoid Arthritis and Systemic Lupus Erythematosus
Tara Skorupa¹ and Robert Shmerling ¹, ¹Beth Israel Deaconess Medical Center / Harvard Medical School, Boston, MA
Background/Purpose: Hydroxychloroquine (HCQ) is a commonly prescribed medication for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and other rheumatic diseases. However, HCQ may cause retinal…
Abstract Number: 322 • 2019 ACR/ARP Annual Meeting
Hydroxychloroquine Retinal Screening and Dosing in an Unique Rheumatologic Patient Population
Leanna Wise¹, Stavros Savvas ² and Elizabeth Ortiz ², ¹LAC+USC/Keck Medicine of USC, Los Angeles, CA, ²LAC+USC/Keck Medicine of USC, Los Angeles
Background/Purpose: Hydroxychloroquine (HCQ) is used in many rheumatologic diseases. The American Academy of Ophthalmology (AAO) put forth guidelines in 2012 regarding retinal screening and dosing…
Abstract Number: 323 • 2019 ACR/ARP Annual Meeting
Compliance with Hydroxychloroquine Dosage According to 2016 American Academy of Ophthalmology (AAO) Guidelines: A Study with 6591 Patients
Thein Swe¹ and Andras Perl ¹, ¹SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: Hydroxychloroquine (HCQ) induced retinal toxicity remains a major concern because it can lead to irreversible damage to retinal pigment epithelium and blindness. American Academy…
Abstract Number: 324 • 2019 ACR/ARP Annual Meeting
Adherence to Guideline Directed Management of Gout Among VA Providers
Kelly Corbitt ¹, Isis Lopez² and David Dillon ³, ¹University of Miami/Jackson Memorial Hospital, Miami, FL, ²University of Miami/ Jackson Memorial Hospital, Miami, FL, ³University of Miami/Jackson Memorial Hospital, Miami
Background/Purpose: Gout is the most common inflammatory arthritis, affecting about 4% of the adult population in the United States. Management is often costly, with estimates around…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].